You may also like
ABIOMED Issues Update on AbioCor Heart Program Status; Clinical Trial To Begin Soon
ABIOMED, Inc. (NASDAQ:ABMD) announced today that while device and team readiness have been demonstrated for several weeks, the first human implantation of […]
1 min read
Coronary Artery Bypass Grafting on the Beating Heart: Surgical Revascularization for the Next Decade?
Whether it will ultimately replace conventional CABG, however, is dependent on the results of long-term patency studies and the wider development of adequate training programmes.
1 min read
Hetastarch Increases the Risk of Bleeding Complications in Patients After Off-Pump Coronary Bypass Surgery: A Randomized Clinical Trial
Hetastarch is an artificial colloid widely used intraoperatively in fluid-replacement regimens. Previous studies have found that the intraoperative administration of hetastarch may increase the risk of postoperative bleeding in patients who undergo coronary artery bypass graft surgery with cardiopulmonary bypass.
1 min read